|
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase III, Phase II
|
|
|
|
Treatment
|
|
|
|
Active
|
|
|
|
18 to 70
|
|
|
|
Other
|
|
|
|
UARK 2003-26 NCT00090493
|
|
|
|
|
|
|
|
Last Modified: 9/19/2008  First Published: 11/1/2001 |
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase III
|
|
|
|
Treatment
|
|
|
|
Active
|
|
|
|
30 and under at diagnosis
|
|
|
|
NCI
|
|
|
|
COG-ANBL0032 COG-P9842, NCT00026312
|
|
|
|
|
|
|
|
Last Modified: 9/19/2008  First Published: 11/1/2002 |
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase III
|
|
|
|
Treatment
|
|
|
|
Active
|
|
|
|
16 to 60
|
|
|
|
NCI
|
|
|
|
ECOG-1900 E1900, NCT00049517
|
|
|
|
|
|
|
|
Last Modified: 9/19/2008  First Published: 4/23/2004 |
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase III
|
|
|
|
Treatment
|
|
|
|
Active
|
|
|
|
18 to 60
|
|
|
|
NCI
|
|
|
|
SWOG-S0106 S0106, NCT00085709
|
|
|
|
|
|
|
|
Last Modified: 6/16/2008  First Published: 3/22/2007 |
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase III
|
|
|
|
Treatment
|
|
|
|
Active
|
|
|
|
18 and over
|
|
|
|
Pharmaceutical / Industry
|
|
|
|
VACCINE-PR1-104 UCCRC-14613B, NCT00454168
|
|
|
|
|
|
|
|
Last Modified: 7/7/2008  First Published: 1/16/2007 |
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase III
|
|
|
|
Treatment
|
|
|
|
Active
|
|
|
|
Over 18
|
|
|
|
Other
|
|
|
|
CRUK-TELOVAC-V4 EUDRACT-2006-000461-10, EU-20683, ISRTCN43482138, NCT00425360, TELOVAC
|
|
|
|
|
|
|
|
Last Modified: 8/23/2006  First Published: 4/1/2001 |
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase II, Phase I
|
|
|
|
Treatment
|
|
|
|
Active
|
|
|
|
16 and over
|
|
|
|
Other
|
|
|
|
HOAG-VACCINE-RN NCI-V01-1647, NCT00014131
|
|
|
|
|
|
|
|
Last Modified: 8/23/2008  First Published: 12/1/2001 |
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase II, Phase I
|
|
|
|
Treatment
|
|
|
|
Active
|
|
|
|
18 and over
|
|
|
|
NCI, Other
|
|
|
|
WSU-2006-130 NCT00027807, RWMC-0635146, WSU-010307M1F, WSU-0312004412
|
|
|
|
|
|
|
|
Last Modified: 3/28/2008  First Published: 12/21/2002 |
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase II, Phase I
|
|
|
|
Treatment
|
|
|
|
Active
|
|
|
|
18 and over
|
|
|
|
NCI
|
|
|
|
NCI-03-C-0040 NCI-5762, 03-C-0040, NCT00053170
|
|
|
|
|
|
|
|
First Published: 10/12/2007 |
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase II, Phase I
|
|
|
|
Biomarker/Laboratory analysis, Treatment
|
|
|
|
Active
|
|
|
|
18 and over
|
|
|
|
NCI
|
|
|
|
MSKCC-05077 MSKCC IRB PRotocol #05-077, NCT00546377
|
|
|
|